Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant

Ashley McEwan1, Omali Pitiyarachchi1,2, Nicholas Viiala1,3

Correspondence: Ashley McEwan (e-mail: Ashley.mcewan@health.nsw.gov.au).

T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a malignant neoplasm of immature T-cells with characteristic immunophenotypic subtypes that correspond to T-cell maturation stages. Early T-cell precursor lymphoblastic leukemia (ETP-ALL) is one such subtype, which is derived from thymic cells at the early T-cell precursor differentiation stage and make up 5% to 16% of T-ALL cases.1 ETP-ALL cells are derived from hematopoietic stem cells that have recently migrated to the thymus, and retainmultilineage pluripotency.2 They display reduced expression of T cell antigens; typically CD1a(−), CD5(−/dim) and CD8(−), and display aberrant expression of stem cell or myeloid antigens.3 Congruently, the genetic mutations seen in ETP-ALL are similar to those found in poorly differentiated myeloid neoplasms and mixed phenotype T/myeloid acute leukemia.4 Historically, ETP-ALL has a poor prognosis with standard chemotherapy but similar outcomes to T-ALL are reported when treated with contemporary protocols.5 Recent research has described how ETP-ALL both expresses and is dependent on BCL2, and hence how antagonists such as ABT-199 (venetoclax) may offer a potential therapeutic benefit.6 We report a patient with relapsed/refractory ETP-ALL, with defined molecular mutations on next generation sequencing (NGS) at the time of relapse, who had an excellent response to venetoclax in combination with nelarabine allowing progression to allogeneic stem cell transplant. We propose this novel treatment strategy is worth further investigation, especially in light of adverse outcomes seen in this disease.

In this report, we describe a case of relapsed/refractory ETP-ALL that responded to the combination of venetoclax and nelarabine, when administered as fourth line therapy. The patient remains in remission over 12 months following sibling allogeneic stem cell transplant. A 42-year-old woman was diagnosed with ETP-ALL following axillary lymph node biopsy in April 2016. She presented with mild thrombocytopenia and generalized lymphadenopathy in the absence of constitutional symptoms. Biopsy findings were consistent with ETP-ALL (as shown in Fig. 1), with an immunophenotype expressing CD2, CD7, CD34, cytoplasmic CD3, CD13 and negative for surface CD3, CD1a, CD4, CD8, MPO and TdT. FDG-PET/CT at diagnosis showed stage 3 disease with widespread intense FDG-uptake. Less than 1% of BM cells were of the same phenotype as the lymph node biopsy. BM cytogenetic analysis revealed a germ line mutation with a balanced translocation between chromosome 15q22 and 21q22 in all cells, confirmed on subsequent evaluation of peripheral blood lymphocytes. This is clinically insignificant in carriers and without evidence of association with ETP-ALL. Baseline investigations also detected chronic hepatitis B infection with viremia and tenofovir, as treatment and ongoing prophylaxis, was commenced prior to chemotherapy.

She commenced first line therapy with hyperCVAD and alternating high dose methotrexate and cytarabine, intended to be an eight-cycle treatment course, but limited to six cycles due to complications with bacterial sepsis, liver function derangement and delayed count recovery. FDG-PET/CT performed after 3 cycles and at the completion of 6 cycles demonstrated complete metabolic response. Maintenance therapy with POMP was then commenced, but our patient relapsed during her 14th cycle. Her relapse was characterized by enlarging mediastinal lymph nodes, intensely FDG avid on PET/CT and correlating to involved nodes at diagnosis. Relapse was confirmed by lymph node biopsy and repeat bone marrow biopsy now showed extensive infiltration with 30% involvement with ETP-ALL (shown in Fig. 1), consistent with the diagnostic immunophenotype (Fig. 1). DNA from this bone marrow sample was later extracted to perform NGS analysis.

Second-line chemotherapy was commenced in January 2018 with FLAG-Ida, as per institutional guidelines, achieving a partial response with bone marrow biopsy detecting 5% blasts on morphology, and 3% ETP-ALL on flow cytometry. FDG-PET/CT imaging post FLAG-Ida demonstrated small volume residual disease within the scapula and clavicle but no uptake in lymph nodes. An inflammatory pulmonary nodule was noted, concerning
for possible invasive fungal infection, and for which she received voriconazole therapy. However, in the interval between clearance of infection, acceptance for transplantation, and her conditioning regimen, her disease progressed, with pre-transplant marrow showing 11% lymphoblasts on flow cytometry.

Single agent nelarabine was commenced as third-line chemotherapy utilizing the protocol described by Berg et al. After 1 cycle of nelarabine, 10% ETP-ALL remained within the bone marrow, which was deemed an insufficient response to proceed on to stem cell transplant. After overt progression of lymphadenopathy, she was subsequently treated with palliative intent with a further cycle of nelarabine, 2 months after her first cycle. Her adenopathy responded partially to the second cycle of nelarabine, and bone marrow biopsy detected 14% ETP-ALL.

In the absence of curative therapeutic options, the patient was offered a novel approach of venetoclax in addition to nelarabine therapy 1 month later in August 2018. Venetoclax was commenced with her third cycle of nelarabine escalating the dose from 200 mg to 400 mg daily, over 3 days. The regimen was commenced with her third cycle of nelarabine escalating the dose from 200 mg to 400 mg daily, over 3 days. The regimen was well tolerated with no tumor lysis or significant neurotoxicity but moderate cytopenias requiring transfusion support. Posaconazole was added from Day +14, while tenofovir prophylaxis continued throughout. Bone marrow biopsy performed on Day +25 of venetoclax and nelarabine demonstrated morphological complete remission without detectable ETP-ALL by flow cytometry, although no MRD testing was performed. Clinically, there was complete resolution of all lymphadenopathy, but FDG-PET/CT showed abnormal low level uptake in two normal sized cervical lymph nodes and moderate residual focus in the bone marrow, which was deemed an insufficiency response to proceed to allogeneic SCT. She continued on venetoclax 400mg daily for a total duration of 2 months. In October 2018, given doubt over the PET scan, radiation therapy was administered to the sternum, and was followed by conditioning with Cyclophosphamide/Total Body Irradiation, and Sibling Allogeneic Transplant. She remains in remission over 12 months following transplant.

To our knowledge this is one of the first cases of venetoclax used in combination with nelarabine to achieve remission in a patient with relapsed/refractory ETP-ALL. Nelarabine is a deoxyguanosine analog which results in a cytotoxic effect against T lymphoblasts. It is a well-recognized salvage therapy for relapsed/refractory T-ALL albeit resulting in a dismal OS in the absence of Allogeneic Stem Cell Transplant (54% OS with allogeneic-SCT vs 22% without). In this report, the ETP subset was not delineated. Of notable concern is reported cases of irreversible nelarabine neurotoxicity, fortunately not experienced by our patient.

In our patient, Venetoclax, a BH3 mimic, which inhibits the anti-apoptotic protein BCL-2, was added to a standard salvage regimen of nelarabine. BCL-2 shows high expression in early T-cell precursors and gradually decreases during normal T-cell differentiation. Hence the degree of response to venetoclax may be mediated by the stage of differentiation arrest of the leukemic T cells. The patient discussed had a significant expression of BCL-2 (Fig. 1), which has been shown to correlate with response to venetoclax.

Several reports have demonstrated the efficacy of venetoclax in combination with other cytotoxic therapies in the setting of relapsed/refractory ETP-ALL and with nelarabine. Despite poor response to single agent nelarabine, our patient was treated with the combination of venetoclax and nelarabine due to the potential synergistic effects of cytotoxicity to T lymphoblasts combined with BCL-2 inhibition, and as an extension of the current widely accepted treatment for relapsed T-ALL. There are several clinical trials currently underway to investigate the use of venetoclax with cytotoxic chemotherapy for the treatment of T-ALL.

Retrospectively, genetic variant data was obtained from DNA extraction, and subsequent next generation sequencing performed on archived bone marrow slides to highlight the distinct genetic profile of ETP-ALL (shown in Table 1). Mutations were detected in the RAS signalling pathway (missense mutations in both JAK1 and JAK3) which have been reported by Zhang et al. in 67% of ETP-ALL compared to 19% of non-ETP-ALL. EZH2 mutations have been shown to increase RAS pathway-associated transcription, potentially creating a transcriptional environment susceptible to other genetic mutations, increasing proliferation. Two missense mutations in EZH2 were detected which affect histone modification, whom Braggio reported in 42% of ETP-ALL cases compared with 12% of non-ETP-ALL cases. A nonsense mutation in PHF6 was also detected. PHF6 mutations have been characterized as a potential early driver mutation in the pathogenesis of T-ALL, as it is implicated in the
Table 1

| Gene   | Variant       | Variant Analysis                                    |
|--------|---------------|-----------------------------------------------------|
| ASXL1  | c. 1934dup; p.(Gly646Trpfs*12) | A frameshift mutation was detected in ASXL1 predicted to result in a truncated protein product. |
| JAK3   | c. 1533>G; A->p. (Met511Ile) | A Met511Ile missense mutation was detected in JAK3 which is an established activating mutation in JAK3. |
| PHF6   | c. 442>G; T->p. (Glu148Asp) | A nonsense mutation was detected in PHF6 predicted to result in a truncated protein product. |
| AKI1   | c. 2689>G; A->p. (Glu897Asp) | A missense mutation was detected in AKI1 – which is an activating mutation. |
| TET2   | c. 5620>G; A->p. (Pro1874Gln) | A missense mutation was detected in TET2. |
| EZH2   | c. 1730>G; T->p. (Pro577Leu) | Two missense mutations were detected in EZH2, Pro577Leu and Asp154Val. |
| ASXL1  | c. 461>A; T->p. (Asp154Val) | A missense mutation was detected in ASXL1. |

**Table 1** Variants Detected in our Patient on PanHaem NGS Panel (Peter MacCallum Cancer Centre)

DNA is analyzed by targeted gene sequencing of coding regions and flanking splice sites (within 2 kb) of the genes listed below. Libraries are prepared using the KAPA Hyper Prep Kit and enriched using an Agilent SureSelectXT Custom Capture Panel (Peter MacCallum Cancer Centre PanHaem version 2) and sequenced on an Illumina NextSeq500 with 75 bp paired end reads. A Seqline-framework analysis pipeline is used to generate aligned reads and call variants against the hg19 human reference genome. Variants are described according to HGVS nomenclature (www.hgvs.org). Potential pathogenic variants passing multiple functional and quality filters are reported. This assay does not distinguish between somatic and germline variants. Copy number variations, structural rearrangements, or aneuploidies are not reported. The detection limit of this assay for unpaired specimens sequenced to the target read depth of 150x is a variant allele frequency of approximately 20%.

* Sample performed on DNA extracted on 23/9/19 from bone marrow aspirate slides from sample collected on 3/1/2018.

self-renewal and homeostasis of hematopoietic stem cells.**Lastly, frameshift mutation in ASXL1 and missense mutation in TET2 were detected which affect epigenetic regulation of gene expression. These are classically seen in myeloid disorders but reported at low frequency in T-ALL with TET 2 mutations were detected which affect epigenetic regulation of gene frameshift mutation in ASXL1 and missense mutation in TET2.

Genetic mutations, similar pattern to leukemic stem cells and granulocyte precursors mutations re...

ASXL1 c. 1934dup; p.(Gly646Trpfs*12)  A frameshift mutation was detected in ASXL1 predicted to result in a truncated protein product.

JAK3 c. 1533>G; A->p. (Met511Ile)  A Met511Ile missense mutation was detected in JAK3 which is an established activating mutation in JAK3.

PHF6 c. 442>G; T->p. (Glu148Asp)  A nonsense mutation was detected in PHF6 predicted to result in a truncated protein product.

AKI1 c. 2689>G; A->p. (Glu897Asp)  A missense mutation was detected in AKI1 – which is an activating mutation.

TET2 c. 5620>G; A->p. (Pro1874Gln)  A missense mutation was detected in TET2.

EZH2 c. 1730>G; T->p. (Pro577Leu)  Two missense mutations were detected in EZH2, Pro577Leu and Asp154Val.

Coccoro N, Anelli L, Zagaria A, et al. Next-generation sequencing in acute lymphoblastic Leukemia. Int J Mol Sci. 2019;20:22929.

Ni Chonghaile T, Roderick JE, Glenfield C. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074–1087.

**Acknowledgements**

The authors thank the Liverpool Hospital clinical flow cytometry scientist Neil McNamara, for help with flow cytometry data.

**References**

1. Vadillo E, Dorantes-Acosta E, Pelayo R, et al. T-cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. 2018;32:36–51.

2. Jain N, Lamb AV, O’Brien S. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–1869.

3. Coustan-Smith E, Mullighan GC, Onciu M. Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol. 2009;10:147–156.

4. Coccoro N, Anelli L, Zagaria A, et al. Next-generation sequencing in acute lymphoblastic Leukemia. Int J Mol Sci. 2019;20:22929.

5. Ni Chonghaile T, Roderick JE, Glenfield C. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074–1087.

6. Berg SL, Blaney SM, Devidas M. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the children’s oncology group. J Clin Oncol. 2005;23:3376–3382.

7. Candoni A, Lazzarotto D, Curti A. Nelarabine as Salvage Therapy and Bridge to Allogeneic Stem Cells Transplantation in 118 adult patients with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. A Cambridge University Hospital study. Leukemia. 2009;10:147–150.

8. Hartz B, Löbel U, Hagel C, et al. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am J Hematol. 2018;93:1287–1289.

9. Peirs S, Matthijsens F, Goossens S. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738–3747.

10. Numan Y, Alfayez M, Maiti A. First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2018;2:101200.

11. Richard-Carpentier G, Jabbour E, Short NJ. Clinical experience with venetoclax in combination with chemotherapy for relapsed/refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:212–216.

12. Jabbour E. Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia. Texas, United States; 2019. https://clinicaltrials.gov/ct2/show/NCT03980861. Accessed January 01, 2020.

13. Zhang J, Ding L, Holmfeldt L. The genetic basis of early T-cell precursor acute lymphoblastic leukemia. Nature. 2012;481:157–163.

14. Braggio E, Egan JB, Fonseca R, et al. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 2013;3:e127.